Skip to main content

Table 2 Clinical and pathological features associated with the metastatic tumors

From: BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor

  M0 at presentation
(N = 90)
M1
(N = 68)
Total
(N = 158)
Year of Metastasectomy
 Median 1999 1998 1999
 Range (1991–2005) (1990–2004) (1990–2000)
Metastatic Site
 BONE 9 (10.0%) 10 (14.7%) 19 (12.0%)
 BOWEL 1 (1.1%) 0 (0.0%) 1 (0.6%)
 BRAIN 7 (7.8%) 4 (5.9%) 11 (7.0%)
 CONTRALATERAL ADRENAL 3 (3.3%) 5 (7.4%) 8 (5.1%)
 HEART 0 (0.0%) 1 (1.5%) 1 (0.6%)
 IPSILATERAL ADRENAL 2 (2.2%) 8 (11.8%) 10 (6.3%)
 LIVER 4 (4.4%) 5 (7.4%) 9 (5.7%)
 MUSCLE 0 (0.0%) 1 (1.5%) 1 (0.6%)
 NON-REGIONAL NODES 9 (10.0%) 1 (1.5%) 10 (6.3%)
 OMENTUM 0 (0.0%) 1 (1.5%) 1 (0.6%)
 OTHER 6 (6.7%) 8 (11.8%) 14 (8.9%)
 PANCREAS 5 (5.6%) 2 (2.9%) 7 (4.4%)
 PULMONARY 40 (44.4%) 20 (29.4%) 60 (38.0%)
 SKIN 2 (2.2%) 2 (2.9%) 4 (2.5%)
 SPLEEN 1 (1.1%) 0 (0.0%) 1 (0.6%)
 THYROID 1 (1.1%) 0 (0.0%) 1 (0.6%)
Metastatic Grade
 2 16 (17.8%) 13 (19.1%) 29 (18.4%)
 3 60 (66.7%) 36 (52.9%) 96 (60.8%)
 4 14 (15.6%) 19 (27.9%) 33 (20.9%)
Metastatic Necrosis
 No 57 (63.3%) 38 (55.9%) 95 (60.1%)
 Yes 33 (36.7%) 30 (44.1%) 63 (39.9%)
Metastatic Sarcomatoid
 No 86 (95.6%) 62 (91.2%) 148 (93.7%)
 Yes 4 (4.4%) 6 (8.8%) 10 (6.3%)